On July 23, Lindsay Bealor Greenleaf, Vice President and Solution Leader, Federal and State Policy at ADVI Health, spoke with Politico to discuss how Vice President Harris might shift the healthcare landscape in the 2024 Presidential Election. In the interview, Lindsay states that Medicare’s new authority to negotiate drug prices under the Inflation Reduction Act could become a key focus for a potential Harris presidency, posing a challenge for the pharmaceutical industry. Harris might highlight this as a shared achievement with President Biden. Lindsay also suggested that Harris’ approach to implementing drug-related provisions in the IRA could be more aggressive than the current administration’s. Finally, she talked about “march-in rights,” which allow the government to seize patents on high-cost drugs to increase competition and reduce prices. Although the Biden administration has not yet used this power, it has affirmed its right to do so.

You can read more of Lindsay’s insights in Politico.